M17.4 Insurance Policy Changes

ICD-10 M17.4 is officially defined as "Other bilateral secondary osteoarthritis of knee." code M17.4 is referenced in 9 tracked payer policy changes from Independence Blue Cross, Health Net, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code M17.4 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Independence Blue Cross · Effective Dec 1, 2025High impact
11.14.07y, Intra-Articular Injection of Hyaluronan for the Treatment of Osteoarthritis
Independence Blue Cross updated policy 11.14.07y to version 11.14.07z effective 12/01/2025, removing four unspecified laterality ICD-10 diagnosis codes (M17.10, M17.30, M17.5, M17.9) and aligning coverage criteria with FDA labeling and Novitas LCD L35529 recommendations. Billing teams must stop using the removed diagnosis codes and ensure claims use only the specified laterality codes (M17.0, M17.11, M17.12, M17.2, M17.31, M17.32, M17.4) for hyaluronan intra-articular injections.
Health Net · Identified Jun 20, 2026High impact
21-139 Medical Policies - 4th Quarter 2020
Health Net updated multiple medical policies in Q4 2020, affecting prior authorization requirements, coverage criteria, and billing codes across numerous specialties including oxygen therapy, allergy testing, bariatric surgery, wound care, and various diagnostic procedures.
Health Net · Identified Jun 20, 2026High impact
21-142 Medical Policies - 4th Quarter 2020
CalViva Health updated multiple medical policies for Q4 2020 affecting prior authorization requirements, coverage criteria, and billing codes across numerous specialties. Key changes include revised oxygen therapy criteria, new ambulatory surgery center redirection requirements, updated bariatric surgery protocols, and modified coverage for various diagnostic and therapeutic services.
Independence Blue Cross · Effective Dec 1, 2025Medium impact
MA11.023l, Hyaluronan Therapies for Osteoarthritis of the Knee
Independence Blue Cross updated MA policy MA11.023l to MA11.023m effective 12/01/2025, aligning hyaluronan therapy coverage with FDA labeling and Novitas LCD L35529 recommendations. Four unspecified laterality diagnosis codes (M17.10, M17.30, M17.5, M17.9) were removed from the approved coding table, requiring claims to use only laterality-specific codes going forward.
Aetna · Identified Oct 6, 2026Medium impact
Viscosupplementation (CPB 0179, reviewed 2026-09-02)
Aetna Clinical Policy Bulletin 0179 covers viscosupplement (hyaluronate) injections for knee osteoarthritis under commercial medical plans, and considers all other indications experimental, investigational, or unproven. Initial approval requires radiographic evidence of knee osteoarthritis or at least five listed signs and symptoms, knee pain that interferes with functional activities, an inadequate response or adverse effects with non-pharmacologic treatment, an inadequate response, intolerance or contraindication to an analgesic trial for at least 3 months, an inadequate response, intolerance or contraindication to intra-articular steroid injections for at least 3 months, and no total knee replacement scheduled within 6 months of starting treatment. Continuation requires improvement in pain and functional capacity after prior injections and at least 6 months since the last injection in the prior completed series. the policy was last reviewed 09/02/2026, and its next review is listed for 01/28/2027.
Aetna · Identified Aug 19, 2026Medium impact
Viscosupplementation (CPB 0179, reviewed 2026-04-02)
Aetna considers viscosupplement (hyaluronate) injections medically necessary for commercial medical plans to treat knee osteoarthritis when all of the following criteria are met: radiographic evidence of knee osteoarthritis or at least 5 of the listed signs and symptoms, knee pain that interferes with functional activities, an inadequate response or adverse effects from non-pharmacologic treatment, an inadequate response, intolerance or contraindication to at least 3 months of an analgesic trial and to at least 3 months of intra-articular steroid injections, and no total knee replacement scheduled within 6 months of starting treatment. Continuation is considered medically necessary when the member meets the initial criteria, has improved in pain and functional capacity after the previous injections, and at least 6 months have passed since the last injection in the prior completed series. Aetna considers all other indications experimental, investigational or unproven, and precertification may apply to viscosupplementation products for Aetna participating providers and members in applicable plan designs.
Independence Blue Cross · Effective Apr 1, 2026Low impact
MA08.097a, Triamcinolone Acetonide ER Injectable (Zilretta®)
This is a routine annual reissue of the Independence Blue Cross Medicare Advantage policy for Zilretta (Triamcinolone Acetonide ER Injectable) with no substantive changes to coverage criteria, medical necessity requirements, or billing codes. The policy continues to cover Zilretta for knee osteoarthritis when specific clinical criteria are met, and repeat injections remain non-covered/experimental.
Independence Blue Cross · Effective Jan 2, 2026Low impact
MA11.023m, Hyaluronan Therapies for Osteoarthritis of the Knee
Independence Blue Cross updated HCPCS code J7322 to include a new product variant 'Hymovis One' alongside the existing 'Hymovis' product for hyaluronan knee injections. This is a coding descriptor update effective 01/02/2026 that affects how claims for this specific hyaluronan product are billed and processed.
Independence Blue Cross · Identified Jun 19, 2026Low impact
08.01.47a, Triamcinolone Acetonide Extended-Release Injectable (Zilretta®)
Independence Blue Cross reissued Policy 08.01.47a on 04/01/2026 with no substantive changes to Zilretta (triamcinolone acetonide ER injectable) coverage. The policy continues to cover the medication for knee osteoarthritis under HCPCS code J3304 when specific medical necessity criteria are met, including prior conservative therapy and intra-articular steroid injection failure. Repeat administrations and off-label uses remain non-covered unless supported as accepted off-label indications.

Watch M17.4

Get one email when a payer policy names M17.4, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code M17.4?

There are 9 tracked policy changes affecting code M17.4, including updates from Independence Blue Cross, Health Net, Aetna. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code M17.4?

Payers that have issued tracked updates for code M17.4 include: Independence Blue Cross, Health Net, Aetna.

How do I get notified when code M17.4 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code M17.4. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code M17.4?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

11.14.07y, Intra-Articular Injection of Hyaluronan for the Treatment of Osteoarthritis

21-139 Medical Policies - 4th Quarter 2020

21-142 Medical Policies - 4th Quarter 2020

MA11.023l, Hyaluronan Therapies for Osteoarthritis of the Knee

Viscosupplementation (CPB 0179, reviewed 2026-09-02)

Viscosupplementation (CPB 0179, reviewed 2026-04-02)

MA08.097a, Triamcinolone Acetonide ER Injectable (Zilretta®)

MA11.023m, Hyaluronan Therapies for Osteoarthritis of the Knee

08.01.47a, Triamcinolone Acetonide Extended-Release Injectable (Zilretta®)

What insurance policy changes affect code M17.4?

Which payers have updated policy for code M17.4?

How do I get notified when code M17.4 policy changes?

Why do payers change policies for code M17.4?